Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era
In conclusion, we found that the clinical outcome of patients with relapsed/refractory DLBCL in the rituximab era was unsatisfactory. Further improvements in treatment strategies, including novel agents, are needed.
Source: Annals of Hematology - Category: Hematology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Lymphoma | Rituxan | Transplants